Faculty Collaboration Database

Inhibition of small intestinal secretion by cannabinoids is CB1 receptor-mediated in rats. Eur J Pharmacol 2000 Dec 08;409(2):207-11

Date

12/06/2000

Pubmed ID

11104836

DOI

10.1016/s0014-2999(00)00843-8

Scopus ID

2-s2.0-0034624257 (requires institutional sign-in at Scopus site)   57 Citations

Abstract

We tested the hypothesis that cannabinoids, acting via a neuronal mechanism of action decrease small intestinal secretion. In vitro electrical stimulation induced ileal secretion in rats, that was attenuated by a cannabinoid receptor agonist, WIN 55212-2, (mesylate(R)-(+)-[2, 3-dihydro-5-methyl-3-[4-morpholino)methyl]pyrrolo-[1,2,3-de]-1, 4-benzoxazin-6-yl](1-naphthyl)methanone) but not its optical isomer WIN 55212-3. The inhibition of secretion induced by WIN 55212-2 was reversed by SR141716A (N-(piperidin-1-yl)-5-(4-chlorophenyl)-1(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride), a cannabinoid CB1 receptor antagonist. An ileal secretory response stimulated by acetylcholine was unaffected by WIN 55212-2. These findings show that cannabinoids inhibit neurally mediated secretion via cannabinoid CB1 receptors. Thus, cannabinoids may have therapeutic potential for diarrhea unresponsive to available therapies.

Author List

Tyler K, Hillard CJ, Greenwood-Van Meerveld B

Author

Cecilia J. Hillard PhD Associate Dean, Center Director, Professor in the Pharmacology and Toxicology department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Acetylcholine
Animals
Benzoxazines
Cannabinoids
Dose-Response Relationship, Drug
Electric Stimulation
Ileum
In Vitro Techniques
Intestine, Small
Male
Morpholines
Naphthalenes
Piperidines
Pyrazoles
Rats
Rats, Sprague-Dawley
Receptors, Cannabinoid
Receptors, Drug